Paediatricians' decision making about prescribing stimulant medications for children with attention‐deficit/hyperactivity disorder

Chow, Sally; Sciberras, Emma; Gillam, Lynn; Green, Julie; Efron, Daryl

doi:10.1111/cch.12036

Cited by 5 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The censusADHD study was established to recruit a nationwide cohort of Australian children aged 6–11 years living with ADHD. As expected from previous reports (Chow et al, 2014), almost two-thirds of the index children were first diagnosed with ADHD by paediatricians. Consistent with other population-based studies (Bianchini et al, 2013; Rowland et al, 2015), the proportion of index children of each ADHD subtype was as expected, indicating that the sample is representative of the DSM-IV diagnostic criteria for ADHD cases in the population.…”

Section: Discussionsupporting

confidence: 87%

“…In Australia, the treatment and management of ADHD are predominantly undertaken by paediatricians (Chow et al, 2014); approximately 92% of patients with ADHD receive treatment under the care of a paediatrician rather than a psychiatrist or general practitioner (Preen et al, 2008). Current international guidelines recommend multimodal approaches that include pharmacological and psychosocial interventions for the management of ADHD (Coghill et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

censusADHD Study: An Australian-wide medication-based recruitment study for Attention-Deficit/Hyperactivity Disorder

Lind

Medland

2022

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Objective: Attention-deficit/hyperactivity disorder affects over 5% of children and is characterised by a persistent pattern of problems with focussing or maintaining attention and/or hyperactivity-impulsivity. The censusADHD Study is a richly phenotyped nationwide cohort of Australian children with attention-deficit/hyperactivity disorder. The overarching aims of the study are to examine attention-deficit/hyperactivity disorder medication utilisation patterns and treatment response, the impact of children’s attention and behavioural problems on caregivers, and costs related to attention-deficit/hyperactivity disorder. Methods: Families of potential attention-deficit/hyperactivity disorder cases aged between 6 and 11 years were identified using Pharmaceutical Benefits Scheme prescription records for attention-deficit/hyperactivity disorder medications held by Services Australia and sent a study information letter. Data were collected from 1574 primary caregivers via online survey in 2015, including the behavioural profile of the child, the child’s medication use and experiences with side effects and the impact of the child’s behaviour on the caregiver. Approximately 81% of caregivers also consented to record linkage of the child’s Pharmaceutical Benefits Scheme and Medicare Benefits Schedule claims to directly assess prescription dispensing history and health service usage to estimate costs to the family and Medicare health system. Results: Boys were diagnosed with attention-deficit/hyperactivity disorder earlier ( p = 0.021), more likely to present as the combined and predominantly hyperactive subtypes ( p = 0.001) and at higher risk of experiencing a school suspension ( p < 0.001) or expulsion ( p = 0.043). Overall, children presenting as the combined subtype had higher rates of psychiatric comorbidities ( p < 0.001). Finally, prescription costs for each family and the Pharmaceutical Benefits Scheme significantly increased in the year following attention-deficit/hyperactivity disorder diagnosis ( p < 0.001). Conclusion: Research examining the psychosocial and financial impact of attention-deficit/hyperactivity disorder on Australian children and their families is needed. Our findings demonstrate the importance of examining both gender and attention-deficit/hyperactivity disorder subtype presentation in future studies.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

censusADHD Study: An Australian-wide medication-based recruitment study for Attention-Deficit/Hyperactivity Disorder

Lind

Medland

2022

Aust N Z J Psychiatry

View full text Add to dashboard Cite

show abstract

“…An interview-based study done in Australia in 2014 to evaluate paediatricians' decision making about stimulant prescribing showed it to be a complex process. 18 They found that there are clinical, child/family and paediatrician factors, all of which are weighed up before a decision is made. In the paediatrician factors, previous experience and success with the medication were important.…”

Section: Discussionmentioning

confidence: 99%

Who is prescribing psychotropic medications in a public developmental–behavioural clinical service and how often?

Hughes

Roberts

2019

J Paediatrics Child Health

View full text Add to dashboard Cite

Aim: Psychotropic prescribing by paediatricians is increasingly common, and there is considerable variation in care provided. The aims of this study were to examine current rates of psychotropic prescribing in the developmental-behavioural outpatient clinics at the Royal Children's Hospital's Centre for Community Child Health, and to compare rates between paediatric consultants and advanced trainees. Methods: Data were extracted for appointment encounters from electronic medical records across 12 months in 2017. Patient demographics, provider and medication order data were analysed using Excel and STATA to calculate logistic regression, standard deviation, percentages and means. Results: From 5069 encounters, there were 847 (16.7%) that included psychotropic prescribing. Advanced trainees prescribed psychotropic medications in only 4.4% of their encounters compared with consultants who prescribed these medications in 23% of encounters (P < 0.001). Stimulants were the most commonly prescribed psychotropic medication (62%), either alone (86.3%) or in combination (13.7%).Conclusions: Psychotropic prescribing rates were lower than expected. Advanced trainees may need more experience in psychotropic prescribing.

show abstract

Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France

Courtabessis

Pupier

Surig

et al. 2017

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

European guidelines advise on best practices for the diagnosis and non-pharmacological and pharmacological treatment of attention-deficit hyperactivity disorder (ADHD). This study aimed to (1) assess whether clinician's decisions to initiate methylphenidate treatment in children diagnosed with ADHD are in accordance with European guidelines and (2) identify clinical factors associated with the decision to recommend methylphenidate prescription. 5 to 13-year-old patients with an ADHD diagnosis were consecutively evaluated in an outpatient child and adolescent psychiatry clinic in France. Patients underwent a multidisciplinary evaluation including a diagnostic interview, symptom severity assessments with parent questionnaires, and IQ testing. We compared children with (n = 105) and without (n = 55) recommended methylphenidate treatment using Student's t test or Wilcoxon Mann-Whitney test and Chi-square or Fisher's test. Multivariate logistic regression was implemented to determine the respective influence of each variable on treatment recommendation. Recommendation to initiate methylphenidate treatment was associated with (1) ADHD combined presentation, (2) co-occurring Oppositional Defiant Disorder/Conduct Disorder (ODD/CD), Developmental Coordination Disorder (DCD) and Learning Disorder (LD), (3) clinical severity and impairment indicated on parent questionnaires, and (4) reduced perceptual reasoning. Using a multivariate regression model, ADHD combined presentation [combined versus predominantly hyperactive/impulsive and unspecified OR 4.52 (1.23-16.55), p = 0.023], age [OR 1.46 (1.14-1.88), p = 0.003], ODD/CD [OR 5.53 (2.19-14.01), p < 0.001], DCD [OR 4.22 (1.70-10.48), p = 0.002], PRI [OR 0.97 (0.94-0.99), p = 0.01] were significantly associated with recommendation of methylphenidate treatment. Our results indicate that clinicians' treatment decision-making complies with European guidelines and is furthermore associated with the type and severity of ADHD symptoms but also with co-occurring disorders.

show abstract

Paediatricians' decision making about prescribing stimulant medications for children with attention‐deficit/hyperactivity disorder

Cited by 5 publications

References 31 publications

censusADHD Study: An Australian-wide medication-based recruitment study for Attention-Deficit/Hyperactivity Disorder

censusADHD Study: An Australian-wide medication-based recruitment study for Attention-Deficit/Hyperactivity Disorder

Who is prescribing psychotropic medications in a public developmental–behavioural clinical service and how often?

Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France

Contact Info

Product

Resources

About